Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Università Cattolica del Sacro Cuore, Rome, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:5City/State/Province:Rome
Treatments:Biologic therapyHospital:Università Cattolica del Sacro Cuore
Drugs:Journal:Link
Date:Feb 2013

Description:

Patients:
This phase 2 study involved 34 advanced hepatocellular carcinoma patients who had not been previously treated. The median patient age was 68 years and 91.2% were male.

Treatment:
Patients were treated with the biologic therapy agent sunitinib, which is a tyrosine kinase inhibitor that interferes with cancer cell growth.

Toxicities:
There were six treatment-related deaths reported, the causes of which included cirrhosis and liver failure that may not have been related to liver cancer. Grade 4 gastrointestinal bleeding and thrombocytopenia, as well as grade 3 fatigue were also reported.

Results:
The median overall survival was 5.8 months.

Support:
This study was partially supported by Pfizer.

Correspondence: Dr. Carlo Barone; email: [email protected]



Back